Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
20–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Histological/cytological confirmed diagnosis of Gastrointestinal malignancy, except pancreatic cancer
Eligible for 5FU/LV or FOLFIRI chemotherapy
ECOG 0-1
Able to swallow and tolerate tablets
Life expectancy of 3 months
You may not be if
Unwilling to use acceptable method to avoid pregnancy of partner/self for the entire study period and up to 4 weeks after last dose
Women who are pregnant or breastfeeding
Pancreatic cancer
Known brain metastasis, evidence of leptomeningeal disease
History of thrombo-embolic disease
Hemorrhage/bleeding events
Uncontrolled or significant cardiovascular disease
Any 3 or more of the following risk factors: arterial thrombosis , smoking, hypercholesterolemia, hypertension, obesity (BMS\>30) and diabetes
Pre-existing thyroid abnormality, not maintained with medication
QTC (Fridericia) \>450 msec on two consecutive ECG's
Subjects with concomitant second malignancies ( except adequately treated non-melanoma skin, in situ carcinoma of bladder, cervix or breast, early prostate cancer)
Any major surgery within 4 weeks of study drug administration
Increased levels of both D-Dimer and Prothrombin fragment 1 +2
Arm B and C only-positive UGT1A1 genotype of TA7/TA7
History of allergy of brivanib or drug class
History of severe reactions to fluoropyrimidine therapy or irinotecan
Prior therapy with brivanib
Clareo Health | Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)
